PedAM
Pediatric Disease Annotations & Medicines
| Disease | thalassemia |
| Symptom | C0282193|iron overload |
| Sentences | 80 |
| PubMedID- 21452907 | Pharmacoeconomic considerations in treating iron overload in patients with beta-thalassaemia, sickle cell disease and myelodysplastic syndromes in the us: a literature review. |
| PubMedID- 21897589 | This appears to be a common finding in thalassemia with iron overload. |
| PubMedID- 23966805 | Although it was being used in other countries, deferiprone received fda approval only in october 2011 for treatment of patients with transfusional iron overload due to thalassemia syndromes who were not adequately chelated with other agents. |
| PubMedID- 21752315 | Objective: to study the effectiveness and safety of deferasirox (dfx) in the treatment of iron overload in children with beta-thalassemia major. |
| PubMedID- 20450494 | The pathophysiology of thalassaemia is associated with iron overload that generates oxygen free radicals and oxidative tissue injury with ocular vessel alterations. |
| PubMedID- 20631898 | Despite iron overload in patients with β-thalassemia, hepcidin levels are not increased. |
| PubMedID- 25161967 | Background: diabetes mellitus is a major complication of iron overload in patients with beta thalassemia major. |
| PubMedID- 20711357 | The importance of nutritional immunity as it pertains to iron is exemplified by the increased susceptibility to infection of individuals with iron overload due to thalassemia and primary hemochromatosis, two of the most common genetic diseases of humans 3. |
| PubMedID- 21791471 | This study evaluates whether iron overload in patients with beta thalassemia intermedia is associated with morbidity. |
| PubMedID- 20950401 | Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. |
| PubMedID- 23056768 | Objective: hypothyroidism usually appears in the second decade of life and is thought to be associated with iron overload in patients with thalassemia major. |
| PubMedID- 25252297 | Assessment of the relationship between fragmented qrs and cardiac iron overload in patients with beta-thalassemia major. |
| PubMedID- 24087894 | Objective: we aimed to investigate the effect of human hemochromatosis protein (hfe) polymorphisms on cardiac iron overload in patients with beta-thalassemia major. |
| PubMedID- 22391807 | The objective of this review is to discuss the factors which should be considered when designing clinically useful iron chelators, to present the application of iron chelators in the treatment of iron overload associated with beta-thalassaemia major and sickle cell anaemia, and to highlight the potential applications in the treatment of neurodegenerative disorders and microbial infection. |
| PubMedID- PMC3559304 | Myocardial iron overload in patients with sickle-thalassemia has been poorly studied; however, a report has shown no evidence of cardiac iron in a small group (n=10) of multitransfused arab patients. |
| PubMedID- 23830536 | Conclusions: the use of amlodipine in conjunction with standard chelation therapy may suggest a new strategy in preventing and treating iron overload in patients with thalassemia major, especially in organs where iron absorption depends on active uptake by calcium channels like the heart. |
| PubMedID- 22900514 | The complete treatment of transfusional iron overload in thalassaemia using the deferiprone (l1) and deferoxamine combination is a paradigm to be followed in the treatment of many other metal toxicity conditions. |
| PubMedID- 23443782 | Conclusion: magnetic resonance imaging (t2*) detection is an effective and non-invasive means for detecting myocardial and liver iron overload in patients with beta-thalassemia major receiving blood transfusion. |
| PubMedID- 20001472 | Background: pituitary iron overload in patients with transfusion-dependent beta-thalassemia may lead to delayed puberty. |
| PubMedID- 23026844 | Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a uk perspective. |
| PubMedID- 22035015 | Hypogonadotrophic hypogonadism and diminished gonadal reserve accounts for dysfunctional gametogenesis in thalassaemia patients with iron overload presenting with infertility. |
| PubMedID- 21071497 | Continued improvement in myocardial t2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. |
| PubMedID- 22645668 | A study done on status of thyroid function and iron overload in patients with beta thalassemia major on deferoxamine in jordan concluded that there is significantly high (p < 0.05) levels of serum ferritin, ft3, zinc, and copper in patients with beta thalassemia major as compared to controls . |
| PubMedID- 25671931 | Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major. |
| PubMedID- 23028894 | Given the well documented impaired exercise capacity of thalassaemia patients with significant iron overload , , a submaximal exercise testing protocol was adopted. |
| PubMedID- 25616857 | A number of studies have reported heterogeneity of iron distribution in subjects with iron overload due to thalassemia . |
| PubMedID- 25820920 | The deferiprone and deferasirox combination is efficacious in iron overloaded patients with beta-thalassemia major: a prospective, single center, open-label study. |
| PubMedID- 25745550 | This comes in harmony with the results of a previous study that was carried out by cheung et al,28 who found that iron overloading in patients with beta-thalassemia major results in alterations of arterial structures with disruption of elastic tissue and calcification. |
| PubMedID- 20383704 | Augmentation of left atrial contractile function: a herald of iron overload in patients with beta thalassemia major. |
| PubMedID- 25922644 | Hepatic iron overload and fibrosis in patients with beta thalassemia major after hematopoietic stem cell transplantation: a pilot study. |
| PubMedID- 21733147 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. |
| PubMedID- 22665732 | Most of the endocrine complications in thalassaemia are attributable to iron overload which may be the result of economic circumstances (expense of the chelation therapy), late onset of chelation therapy or poor compliance with the iron chelation therapy. |
| PubMedID- 23056717 | Objective: dilated cardiomyopathy is the end result of chronic iron overload in patients with beta thalassemia major. |
| PubMedID- 24919862 | Based primarily on the findings of the thalassa (assessment of exjade((r)) in non-transfusion-dependent thalassemia) trial, the approval for deferasirox has recently been expanded to include the management of chronic iron overload in patients with non-transfusion-dependent thalassaemia (ntdt) syndromes. |
| PubMedID- 24575259 | iron overload in patients with thalassemia is a common feature, which requires continuous chelation therapy and monitoring. |
| PubMedID- 26466432 | Impaired endothelial function in pediatric hemoglobin e/beta-thalassemia patients with iron overload. |
| PubMedID- 21075283 | iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. |
| PubMedID- 21531154 | Combined chelation treatment may be a better approach for transfusion-dependent thalassemia major patients with iron overload complications because of increased efficacy. |
| PubMedID- 23963793 | Authors' conclusions: desferrioxamine is the recommended first-line therapy for iron overload in people with thalassaemia major and deferiprone or deferasirox are indicated for treating iron overload when desferrioxamine is contraindicated or inadequate. |
| PubMedID- 19744128 | The aim of this study was to measure parathormone (pth) and metabolites of vitamin d and consequently to investigate whether these parameters predispose to myocardial iron overload in patients with beta-thalassaemia major. |
| PubMedID- 25402221 | The effects of deferasirox on renal haemodynamics, including glomerular filtration rate (gfr) and renal plasma flow (rpf), were investigated in a phase i, open-label study in beta thalassaemia major patients with iron overload. |
| PubMedID- 25197009 | iron overload in beta-thalassemia major (tm) typically results in iron-induced cardiomyopathy, liver disease, and endocrine complications. |
| PubMedID- 21808992 | Taken together, iron overload in patients with beta-thalassaemia major may potentially result in arterial dysfunction via its effects on the quantity and function of epcs. |
| PubMedID- 22287873 | Cardiac toxicity includes congestive heart failure and arrhythmias and is the leading cause of death related to iron overload in patients with thalassemia major.13 excess iron deposition in the liver leads to inflammation, fibrosis, and cirrhosis,14 which may be further exacerbated by concomitant viral hepatitis, alcohol use, and other hepatotoxins. |
| PubMedID- 24555000 | 1 transfusional hemosiderosis in major thalassemia patients leads to iron overload and then iron deposition in some organs. |
| PubMedID- 23868464 | While dfx has been cited as a factor in a number of treatment-related deaths across several disease areas , no quantitative data were published on thalassaemia patients with transfusional iron overload, and so it was conservatively assumed that dfx was not associated with excess mortality. |
| PubMedID- 21382180 | The value of nontransferrin-bound iron (ntbi) as an index of iron overload in patients with thalassemia has been evaluated; however, data in patients with sickle cell disease (scd) is limited. |
| PubMedID- 25988550 | Background: mri imaging is an alternative to serum ferritin for assessing iron overload in patients with thalassaemia disease. |
| PubMedID- 20813008 | Cardiac magnetic resonance (cmr) has replaced all other surrogate measurements in the determination of transfusional cardiac iron overload in patients with thalassaemia major. |
| PubMedID- 24040004 | iron overload in patients with thalassemia results from both excessive iron absorption and transfusion. |
Page: 1 2